|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
Current Issues
| [26/05/2010] |
| Reimbursed vaccines can provide savings to society » At the moment, the vaccines outside the national vaccination programme are not eligible for the Finnish health insurance reimbursement system (the so-called KELA reimbursement) but must be paid the vaccine-takers themselves. PIF’s analysis focusing on the shingles (Herpes Zoster) vaccines shows that the society could draw economic benefits if this vaccine were to be reimbursed. Indeed, we would urgently need an extensive and neutral study on the economic impacts of potentially reimbursable vaccines. The funding and development of the national vaccination programme should also be ensured. |
| [27/04/2010] |
| One year of reference prices: future focus setting must be a joint effort » |
| [26/02/2010] |
| Price of innovative medicines pressed down by price competition » |
| [08/02/2010] |
| Pharma Industry Finland (PIF) greets new Director of Pharmaceuticals Pricing Board: » |
| [09/11/2009] |
| Pharma Industry Finland: Fimea plays an important role for the development of the entire health care sector » |
| [09/11/2009] |
| PIF comments on the appointment of Director General for Finnish Medicines Agency Fimea: we look forward to versatile co-operation » |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
